Assessment of the Safety and Efficacy of Balstilimab for the Treatment of Relapsed/Refractory Lymphomas (IMMONC0001)

Lymphoma Clinical Trial

Official title:

Assessment of the Safety and Efficacy of Balstilimab for the Treatment of Relapsed/Refractory Lymphomas (IMMONC0001)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05891821
• Other study ID #: IMMONC0001
• Status: Recruiting
• Phase: Phase 2
• Start date: September 1, 2023
• Est. completion date: September 2029

Study information

• Verified date: May 2023
• Source: Immune Oncology Research Institute
• Contact: Astghik Voskanyan, MD
• Phone: +374 (10) 283800
• Email: astghikvos[@]gmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this study is to see if the drug balstilimab is safe and effective in participants with relapsed/refractory lymphomas.

Participants will receive balstilimab every 3 weeks and their outcomes will be assessed periodically.

Description:

This is a single-arm, open-label phase 2 study to evaluate the safety and efficacy of single agent balstilimab in participants with relapsed/refractory lymphoma. The study will enroll participants with relapsed/refractory classical Hodgkin lymphoma or primary mediastinal B-cell lymphoma. The participants will receive balstilimab (BAL) 300 mg IV every 3 weeks. BAL infusions will be administered within 30 minutes (± 5 min) using an infusion pump.

The total estimated maximum time of study participation for each patient is approximately 49 months across 3 periods:

• Screening Period: approximately 28 days

• Treatment Period: up to 24 months, or until any criterion for stopping the study drug or withdrawal from the study occurs

• Follow-up Period: up to 24 months from last dose of study treatment for every patient who is alive

Study Duration

• Recruitment: 2 years

• Treatment: 2 years

• Follow-up: 2 years

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 20
• Est. completion date: September 2029
• Est. primary completion date: September 2029
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Voluntarily agree to participate by giving written informed consent

2. = 18 years of age

3. Have a histologically confirmed diagnosis of a relapsed/refractory classical Hodgkin lymphoma (cHL) or primary mediastinal B-cell lymphoma (PMBCL) for which no standard therapy is available or standard therapy has failed or the patient does not have access to it.

4. Has a life expectancy of at least 3 months and an ECOG performance status of =1 as determined by study Investigator

5. Patients must have sufficient and adequate formalin-fixed tumor tissue sample available that is not older than 3 years; otherwise, a fresh biopsy is required. Archival tissue or fresh biopsy must be from a site not previously irradiated

6. Has adequate organ function defined as the following laboratory values within 7 days of C1D1:

1. Neutrophils = 1500/µL (Must be stable and off any growth factor within 4 weeks of first study treatment administration)

2. Platelets = 75 × 103/µL (transfusion to achieve this level is not permitted within 2 weeks of first study treatment administration)

3. Hemoglobin = 8.0 g/dL (transfusion to achieve this level is not permitted within 2 weeks of first study treatment administration)

4. Creatinine clearance = 30 mL/min as measured or calculated per local institutional standards

5. AST/ALT = 3 × upper limit of normal (ULN)

6. Total bilirubin = 1.5 × ULN (except patients with Gilbert syndrome who must have a total bilirubin level of = 3.0 × ULN)

7. Women of childbearing potential (WOCP) must have a negative serum pregnancy test at Screening (within 7 days before first dose of study drug). Non-childbearing potential is defined as (by other than medical reasons):

1. = 50 years of age and has not menstruated for greater than 1 year

2. Whose status is post hysterectomy, bilateral oophorectomy, or tubal ligation

3. WOCP must be willing to use highly effective methods of contraception (defined in the informed consent form [ICF]) throughout the study, starting with the Screening Visit through 90 days after the last dose of study drug Note: Abstinence is acceptable if this is the established and preferred contraception for the patient.

8. Male patients with a female partner(s) of childbearing potential must agree to use highly effective contraceptive measures throughout the study starting with the screening visit through 90 days after the last dose of study treatment is received. Males with pregnant partners must agree to use a condom; no additional method of contraception is required for the pregnant partner.

9. Is willing and able to comply with the requirements of the protocol

Exclusion Criteria:

1. Has an inadequate period of time prior to first dose of study treatment that is defined as:

1. Received systemic cytotoxic chemotherapy within 3 weeks before initiation of study treatment

2. Received biological therapy or investigational therapy within 4 weeks or 5 circulating halve-lives, whichever is shorter

3. Received small molecule/tyrosine kinase inhibitors within 2 weeks or 5 circulating half-lives, whichever is shorter

4. Received radiation therapy within 3 weeks before initiation of study treatment, except for palliative radiation therapy, which can be received 2 weeks prior to initiation of study treatment

5. Had major surgery within 4 weeks before initiation of study treatment

2. Has gone through disease progression after receiving prior therapy with:

a. Any antibody/drug targeting T-cell co-regulatory proteins (immune checkpoints) such as anti-PD-1 and anti-PD-L1 antibodies

3. Has persisting AEs related to prior immunotherapy of NCI-CTCAE v5.0 Grade = 2 severity.

4. Is expected to require any other form of systemic or localized antineoplastic therapy while on study (including maintenance therapy with another agent, radiation therapy, and/or surgical resection)

5. Has known allergy or hypersensitivity to any component of balstilimab, any history of anaphylaxis, or uncontrolled asthma

6. Has active or history of autoimmune disease that requires systemic treatment within 2 years of the start of study drug (ie, with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs) Note: Patients with autoimmune conditions requiring hormone replacement therapy or topical treatments are eligible.

7. Patients with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) within 14 days or another immunosuppressive medication within 30 days of the first dose of study treatment. Inhaled or topical steroids, and adrenal replacement steroid doses (= 10 mg daily prednisone equivalent) are permitted in the absence of active autoimmune disease.

8. Has had an allogeneic tissue/solid organ transplant

9. Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke or myocardial infarction within 6 months of enrollment, unstable angina, congestive heart failure (New York Heart Association class = III), or serious uncontrolled cardiac arrhythmia requiring medication.

a. QTcF (QTc interval corrected using Fridericia's formula) of > 480 ms.

10. Any evidence of current interstitial lung disease (ILD) or pneumonitis, or prior history of ILD or non-infectious pneumonitis requiring glucocorticoids.

11. Has known untreated hepatitis B/hepatitis C virus (HBV/HCV) or tuberculosis. Active HBV is defined as a known positive hepatitis B surface antigen result. Active HCV is defined by a known positive hepatitis C antibody result and known quantitative HCV RNA results greater than the lower limits of detection of the assay

12. Uncontrolled infection with human immunodeficiency virus (HIV). Patients on stable highly active antiretroviral therapy with undetectable viral load and normal CD4 counts for at least 6 months prior to study entry are eligible. Serological testing for HIV at screening is not required.

13. Has other systemic conditions or organ abnormalities that in the opinion of the Investigator may interfere with the conduct and/or interpretation of the current study

14. Has known psychiatric or substance use disorders that would interfere with cooperation or compromise participation with the requirements of the study

15. Is legally incapacitated or has limited legal capacity

16. Is pregnant or breastfeeding

17. Has received a live/attenuated vaccine within 14 days of first dose of study treatment and other vaccines within 48 hours of first dose of study treatment

18. Has other co-morbidities that would alter risk-benefit of providing balstilimab (determined by treating physician's assessment)

19. Is receiving other therapy that would alter risk-benefit of providing balstilimab (determined by treating physician's assessment)

Related Conditions & MeSH terms

• Lymphoma

Intervention

Drug:
• Balstilimab
An anti-programmed death (ligand) 1 [PD-(L)1] monoclonal antibody

Locations

Country	Name	City	State
Armenia	Hematology Center named after prof. R. Yeolyan	Yerevan

Sponsors (2)

Lead Sponsor	Collaborator
Immune Oncology Research Institute	Agenus Inc.

Country where clinical trial is conducted

Armenia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Objective Response Rate (ORR)	ORR is defined as the percentage of participants with complete response (CR) or partial response (PR) assessed per the Lugano criteria	First dose to up to 27 months
Secondary	Duration of Response (DOR)	DOR is defined as time from first observation of response to first observation of documented disease progression per the Lugano criteria or death within 12 weeks of last tumor assessment	First dose to up to 27 months
Secondary	Disease Control Rate (DCR)	DCR is defined as the percentage of patients who have achieved complete response, partial response or stable disease per the Lugano criteria	First dose to up to 27 months
Secondary	Duration of Stable Disease (SD)	Duration of SD is measured from the start of treatment until the criteria for progression are met, per the Lugano criteria	First dose to up to 27 months
Secondary	Time to Response	Time to Response is defined as the time from the first dose date to first observation of confirmed response per the Lugano criteria	First dose to up to 27 months
Secondary	Progression-Free Survival (PFS) Time	PFS time is defined as time from first treatment administration to first observation of documented disease progression (or death within 12 weeks after last tumor assessment), per the Lugano criteria	First dose to up to 27 months
Secondary	Overall Survival (OS) Time	OS Time is defined as time from start of treatment to death	First dose to up to 48 months
Secondary	Baseline expression of PD-L1 association with ORR	Tumor PD-L1 status will be determined and correlation with ORR will be investigated	First dose to up to 48 months
Secondary	Baseline expression of PD-L1 association with DOR	Tumor PD-L1 status will be determined and correlation with DOR will be investigated	First dose to up to 48 months
Secondary	Baseline expression of PD-L1 association with PFS	Tumor PD-L1 status will be determined and correlation with PFS time will be investigated	First dose to up to 48 months
Secondary	Baseline expression of PD-L1 association with OS	Tumor PD-L1 status will be determined and correlation with OS time will be investigated	First dose to up to 48 months
Secondary	Frequency, severity, and duration of treatment emergent adverse events (TEAEs) and laboratory abnormalities	TEAEs are reported using the National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0	First dose to up to 27 months